Chronic myelogenous leukemia is a disease in which the bone marrow makes too many white blood cells.
Chronic myelogenous leukemia (also called CML or chronic granulocytic leukemia) is a slowly progressing blood and bone marrow disease that usually occurs during or after middle age, and rarely occurs in children.
Normally, the bone marrow makes blood stem cells (immature cells) that develop into mature blood cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell. The lymphoid stem cell develops into a white blood cell. The myeloid stem cell develops into one of three types of mature blood cells:
- Red blood cells that carry oxygen and other materials to all tissues of the body.
- Platelets that help prevent bleeding by causing blood clots to form.
- Granulocytes (white blood cells) that fight infection and disease
In CML, too many blood stem cells develop into a type of white blood cell called granulocytes. These granulocytes are abnormal and do not become healthy white blood cells. They may also be called leukemic cells. The leukemic cells can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. When this happens, infection, anemia, or easy bleeding may occur.
For more information visit the National Cancer Institute website contact the Chemgenex medical information department at our toll free number 1-800-877-3009 X 112 or e-mail us at clinical@chemgenex.com
Omacetaxine CML Clinical Trials
CGX-635-CML-203: A multi-center phase 2 open-label study to evaluate the efficacy and safety of subcutaneous administration of omacetaxine in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase who have failed or are intolerant to two or more tyrosine kinase inhibitors.
CGX-635-CML-202: A multi-center phase II open-label study to evaluate the efficacy and safety of subcutaneous administration of omacetaxine in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase who have tested positive for the T315I bcr-abl point mutation.
CGX-635-CML-201: Phase II open-label study to evaluate the efficacy and safety of intravenous administration of omacetaxine combined with the oral administration of imatinib mesylate in the treatment of patients with chronic myeloid leukemia (CML) in chronic, accelerated and blast phase.
For further information on any of these studies you can log on to www.tkiresistantcml.comalternatively please contact the ChemGenex clinical trials group at our toll free number 1-800-877-3009 X 112 or e-mail us at clinical@chemgenex.com.